Latest GPC Biotech Stories
LONG BRANCH, N.J., June 3 /PRNewswire/ -- The 2009 Pharma ChemOutsourcing Conference & Exhibition attendance is way up again in 2009 and is poised to shatter the attendance record set in 2008.
GPC Biotech has reported preclinical data on RGB-286638, the company's multi-targeted protein kinase inhibitor, that supported the potential utility of RGB-286638 against some hematological malignancies.
GPC Biotech AG (Frankfurt Stock Exchange: GPC, NASDAQ: GPCB) today reported that pre-clinical data on RGB-286638, the Company's multi-targeted protein kinase inhibitor, were presented at the 20th EORTC-NCI-AACR Symposium: Molecular Targets and Cancer Therapeutics in Geneva, Switzerland in a poster entitled, "RGB-286638 is a novel multi-targeted protein kinase inhibitor with activity in chronic myelogenous leukemia (CML) models," (Abstract #578).
GPC Biotech has reported that the company has been informed by its partner for satraplatin in Europe that they plan to withdraw the marketing authorization application for satraplatin plus prednisone for the treatment of hormone-refractory prostate cancer patients whose prior chemotherapy has failed.
GPC Biotech has initiated a Phase II study evaluating satraplatin in combination with the steroid, prednisone, in patients with metastatic hormone-refractory prostate cancer who previously have been treated with docetaxel. The study is being sponsored by the US National Cancer Institute.
Study seeks to determine if presence of certain gene impacts patient outcome GPC Biotech AG Investor Relations & Corporate Communications +49 (0)89 8565-2693 email@example.com or In the U.S.: Laurie Doyle, Director, Investor Relations & Corporate Communications, +1 609-524-5884 firstname.lastname@example.org or Additional media contacts for Europe: MC Services AG Raimund Gabriel, +49 (0) 89 210 2280 email@example.com or Stefan Riedel, +49 (0) 89 210 2280...
- A serpent whose bite was fabled to produce intense thirst.